Moderna’s LP.8.1-adapted COVID-19 vaccine has been recommended by the European Medicines Agency (EMA)’s human medicines ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Moderna has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use ...

Shuhiba Mohammad recently took her daughter for her routine childhood immunizations at age 1, and was frustrated when she was ...

MRNA's second-quarter results are likely to spotlight a sharp decline in Spikevax sales, RSV uptake and key pipeline ...

The European Union's drug regulator has recommended approval of Moderna's updated formulation of COVID-19 shot Spikevax, the ...

Moderna's COVID-19 vaccine has received full approval from the U.S. Food and Drug Administration (FDA) for use in children with medical conditions that put them at higher risk of severe illness.

Moderna's COVID-19 vaccine has long been available for adults in the U.S. and elsewhere and more than three dozen countries offer it to children, too.

Moderna said it started developing its mRNA technology platform in 2010, and that helped the company quickly produce its COVID-19 vaccine after the pandemic arrived in early 2020.

Moderna Inc. on Thursday cut its 2021 sales forecast for its COVID-19 vaccine by as much as $5 billion, as it struggles to ramp up production of its two-dose inoculation, sending its shares down ...

The contaminants found in Moderna COVID-19 vaccines distributed in Okinawa Prefecture are likely bits of rubber accidentally mixed in during the preparation process for the injection.